Adagio Medical Holdings, Inc. (ADGM)
| Market Cap | 18.74M -4.8% |
| Revenue (ttm) | n/a |
| Net Income | -24.37M |
| EPS | -1.33 |
| Shares Out | 22.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,322 |
| Open | 0.8600 |
| Previous Close | 0.8350 |
| Day's Range | 0.8362 - 0.9012 |
| 52-Week Range | 0.7400 - 2.5820 |
| Beta | -0.14 |
| Analysts | Buy |
| Price Target | 3.50 (+314.79%) |
| Earnings Date | May 12, 2026 |
About ADGM
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ADGM stock is "Buy." The 12-month stock price target is $3.5, which is an increase of 314.79% from the latest price.
News
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the trea...
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the tre...
Adagio Medical reports six-month results from Fulcrum-VT IDE trial
Adagio Medical (ADGM) reported six month results from its Fulcrum-VT Investigational Device Exemption, IDE, clinical trial, which will be used to support the Company’s application for Food and Drug Ad...
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #Arrhythmia--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the tre...
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical initiated with an Overweight at Piper Sandler
Piper Sandler analyst Matt O’Brien initiated coverage of Adagio Medical (ADGM) with an Overweight rating and $3 price target The firm says the company has developed a novel ultra-low temperature…
Adagio Medical announces FDA granted IDE approval for FULCRUM-VT trial
Adagio Medical (ADGM) Holdings announced that the U.S. Food and Drug Administration, FDA, has granted Investigational Device Exemption, IDE, approval to expand the Company’s FULCRUM-VT trial to evalua...
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio announces preclinical results for ventricular ablation catheter
Adagio Medical (ADGM) Holdings announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation, ULTA, technology designed to treat ventricular arrhyth...
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature Ventricular Contractions (PVC)
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical to Participate in the 38th Annual Roth Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical highlights favorable safety profile in cardiac ablation study
Adagio Medical (ADGM) announced the publication of results from the U.S. Early Feasibility study evaluating ultralow temperature cardiac ablation for the treatment of scar-related ventricular tachycar...
New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhy...
Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical to Present at the Small Cap Growth Virtual Investor Conference February 5th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhy...
Adagio Medical initiated with a Buy at Lake Street
Lake Street initiated coverage of Adagio Medical (ADGM) with a Buy rating and $4 price target Adagio, which recently released top-line pivotal clinical data for its ultra-low temperature cryoablation ...
Adagio Medical Reports Third Quarter 2025 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhy...
Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...